Teleflex stock analysis
Teleflex (TBH) Stock Price & Analysis
TBH Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 5.55B
- Enterprise Value
- CHF 6.45B
- Total Cash (Recent Filing)
- CHF 430.46M
- Total Debt (Recent Filing)
- CHF 1.68B
- Price to Earnings (P/E)
- 19.9
- Beta
- 0.57
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 1.61
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.81%
Bulls Say, Bears Say
Bulls Say
Recurring Procedure-Driven Demand
Teleflex benefits from recurring consumable demand tied to routine and complex hospital procedures. This replenishment-based model can support durable revenue visibility, while broad clinical applications and hospital formularies provide opportunities to deepen utilization across healthcare systems.
Debt Reduction And Financial Flexibility
Substantially lower debt reduces interest burden and improves flexibility for investment, restructuring, and operating volatility. A stronger capital structure also gives Teleflex greater capacity to fund innovation and manage integration or divestiture-related costs without relying as heavily on additional borrowing.
Product Innovation Pipeline
Regulatory progress on EZPLAZ and Freesolve expands Teleflex's potential growth beyond established products. EZPLAZ addresses emergency plasma use and Freesolve advances interventional therapy, creating differentiated platforms that could support future adoption and broaden the company's clinical relevance.
Bears Say
Revenue And Profitability Deterioration
Recent contraction in revenue and volatile profitability weaken the earnings base and make performance less predictable. Although gross margins remain stable, sustained recovery depends on restoring growth and converting product economics into consistent operating earnings across the portfolio.
Interventional Integration Disruption
The prolonged Interventional integration is constraining growth and absorbing management attention across commercial operations. Continued disruption can delay customer conversion, weaken sales productivity, and postpone the realization of expected acquisition benefits, keeping execution risk elevated over the next several quarters.
Recurring Tariff Exposure
Ongoing tariff costs represent a recurring pressure on profitability rather than a one-quarter issue. With similar exposure expected in 2027 and no comparable offsetting arrangement identified, Teleflex may need pricing, productivity, or portfolio actions to preserve margins against this structural cost headwind.
Teleflex News
TBH FAQ
What is Teleflex’s market cap?
When is Teleflex’s upcoming earnings report date?
How were Teleflex’s earnings last quarter?
Is Teleflex overvalued?
Does Teleflex pay dividends?
What is Teleflex’s EPS estimate?
How many shares outstanding does Teleflex have?
What happened to Teleflex’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Teleflex?
What is the TipRanks Smart Score and how is it calculated?
Teleflex Stock Smart Score
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Jason Weidman
- Employees
- 15,500
- Website
- www.teleflex.com
- Address
- 550 East Swedesford Road, Wayne, PA, 19087-1603, US
Teleflex (TBH) Earnings & Revenues
TBH Company Deck
TBH Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Teleflex delivered better-than-expected third-quarter EPS, expanded margins, reduced leverage, completed significant share repurchases, maintained its revenue outlook, and raised full-year EPS guidance. The company also reported progress on the Interventional integration, organizational transformation, innovation programs, and planned cost savings. These positives were tempered by continued Interventional integration disruption, uncertainty around the timing of the Acute Care and Interventional Urology divestiture, ongoing tariff exposure, near-term R&D and investment-related margin pressure, and the gradual ramp expected for EZPLAZ.
View all CH:TBH earnings summaries









